<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rocuronium: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rocuronium: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Rocuronium: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12110" href="/d/html/12110.html" rel="external">see "Rocuronium: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12774" href="/d/html/12774.html" rel="external">see "Rocuronium: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F219099"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Neuromuscular Blocker Agent, Nondepolarizing</li></ul></div>
<div class="block doa drugH1Div" id="F219073"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose to effect; doses will vary due to interpatient variability. Ensure adequate pain control and sedation prior to and during administration of neuromuscular blockade to achieve deep sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27755068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27755068'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b4ab8ca-f07c-4f28-8a46-61cd9f494e50">Endotracheal intubation or mechanical ventilation during surgery, neuromuscular blockade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endotracheal intubation or mechanical ventilation during surgery, neuromuscular blockade (adjunctive therapy):</b>
<b> Note: </b>Inhaled anesthetic agents prolong the duration of action of rocuronium. Use lower end of the dosing range; redosing interval guided by monitoring with a peripheral nerve stimulator.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Rapid sequence intubation:</b></i>
<b>IV:</b> 1 to 1.2 mg/kg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37196592','lexi-content-ref-31846014','lexi-content-ref-35223887']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37196592','lexi-content-ref-31846014','lexi-content-ref-35223887'])">Ref</a></span>); some experts prefer to use 1.5 mg/kg once, as it may provide higher rates of first-attempt success; however, larger doses increase the duration of action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Caro.2023','lexi-content-ref-33837951','lexi-content-ref-7902034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Caro.2023','lexi-content-ref-33837951','lexi-content-ref-7902034'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Tracheal intubation, non-emergent:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial:</i>
<b>IV: </b>0.6 to 1 mg/kg; usual dosage range: 0.45 to 1.2 mg/kg, depending on desired onset and duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34702332','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34702332','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance: </i>
<b>IV:</b> 0.1 to 0.2 <b>mg</b>/kg; repeat bolus as needed <b>or</b> start a continuous infusion of 5 to 16 <b>mcg</b>/kg/<b>minute</b>; adjust at 15-minute intervals by ~1.5 to 3 <b>mcg</b>/kg/<b>minute</b>; usual dosage range: 4 to 16 <b>mcg</b>/kg/<b>minute</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34702332','lexi-content-ref-30572545','lexi-content-ref-31025258','lexi-content-ref-34750839','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34702332','lexi-content-ref-30572545','lexi-content-ref-31025258','lexi-content-ref-34750839','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6e5c8628-830c-459d-9865-418fbbf3ded5">Mechanically ventilated patients in the ICU, neuromuscular blockade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mechanically ventilated patients in the ICU, neuromuscular blockade (off-label use): Note:</b> May use to facilitate mechanical ventilation (eg, moderate to severe acute respiratory distress syndrome [ARDS]), for refractory, life-threatening status asthmaticus, or for shivering from therapeutic hypothermia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33104824','lexi-content-ref-34605781','lexi-content-ref-27755068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33104824','lexi-content-ref-34605781','lexi-content-ref-27755068'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion: <b>IV:</b> Initial: Loading dose of 0.6 to 1 <b>mg</b>/kg, followed by continuous infusion of 3 to 8 <b>mcg</b>/kg/<b>minute</b> for up to 48 hours; adjust rate by 0.5 to 1 <b>mcg</b>/kg/<b>minute</b> every 60 minutes according to desired clinical response and/or peripheral nerve stimulation; usual dosage range: 3 to 16 <b>mcg</b>/kg/<b>minute</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34281428','lexi-content-ref-33104824','lexi-content-ref-11902255','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34281428','lexi-content-ref-33104824','lexi-content-ref-11902255','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent dosing: <b>IV: </b>Initial: Loading dose of 0.6 to 1 mg/<b>kg</b> (or 50 mg); may repeat with 0.3 to 1 mg/<b>kg</b> (or 25 mg) every 30 to 60 minutes according to desired clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11902255','lexi-content-ref-9135303','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11902255','lexi-content-ref-9135303','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990537"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Although kidney elimination is not the primary route of elimination in patients without kidney dysfunction (predominantly eliminated via the biliary route), decreased clearance (up to 39%) and a prolonged recovery time (up to 84%) have been observed in some studies in patients with severe kidney dysfunction compared to healthy controls (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8123396','lexi-content-ref-19222432','lexi-content-ref-15816565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8123396','lexi-content-ref-19222432','lexi-content-ref-15816565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: No dosage adjustment necessary; however, consider alternative agents or use with caution due to increased interpatient variability and less predictable duration of action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19222432','lexi-content-ref-28814478','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19222432','lexi-content-ref-28814478','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Likely to be dialyzed (extent unknown): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); however, consider alternative agents or use with caution due to increased interpatient variability and less predictable duration of action seen in patients with severe kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8123396','lexi-content-ref-19222432','lexi-content-ref-15816565','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8123396','lexi-content-ref-19222432','lexi-content-ref-15816565','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>Likely to be dialyzed (extent unknown): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); however, consider alternative agents or use with caution due to increased interpatient variability and less predictable duration of action seen in patients with severe kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8123396','lexi-content-ref-19222432','lexi-content-ref-15816565','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8123396','lexi-content-ref-19222432','lexi-content-ref-15816565','lexi-content-ref-Expert.DOR'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); however, consider alternative agents or use with caution due to increased interpatient variability and less predictable duration of action seen in patients with severe kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8123396','lexi-content-ref-19222432','lexi-content-ref-15816565','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8123396','lexi-content-ref-19222432','lexi-content-ref-15816565','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); however, consider alternative agents or use with caution due to increased interpatient variability and less predictable duration of action seen in patients with severe kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8123396','lexi-content-ref-19222432','lexi-content-ref-15816565','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8123396','lexi-content-ref-19222432','lexi-content-ref-15816565','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987854"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling. However, dosage reductions may be necessary in patients with liver disease; duration of neuromuscular blockade may be prolonged due to increased volume of distribution. When rapid sequence intubation is required in adult patients with ascites, a dose on the higher end of the dosage range may be necessary to achieve adequate neuromuscular blockade.</p></div>
<div class="block doo drugH1Div" id="F20330600"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, and 3 obesity (BMI ≥30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Use <b>ideal body weight</b> for weight-based dose calculations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21562423','lexi-content-ref-19690247','lexi-content-ref-28814478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21562423','lexi-content-ref-19690247','lexi-content-ref-28814478'])">Ref</a></span>). In patients with extreme obesity (eg, BMI ≥50 kg/m<sup>2</sup>) or when underdosing is a concern, consider using <b>adjusted body weight</b> for weight-based dosing calculations; however, duration of action may be prolonged (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). In rare situations when emergent therapy is needed (eg, rapid sequence intubation) <b>and</b> adjusted body weight cannot be rapidly calculated, <b>actual body weight</b> may be considered for dose calculations but doses of &gt;250 mg are rarely, if ever, needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Clinicians should <b>not</b> change dosing weight from one weight metric to another during therapy (ie, actual body weight to/from either adjusted body weight or ideal body weight) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Refer to adult dosing for indication-specific doses. If using repeat dosing or continuous infusion after administration of initial dose, titrate to clinical effect.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rationale for recommendations</b></p>
<p style="text-indent:-2em;margin-left:6em;">Nondepolarizing neuromuscular blocking agents (NMBAs) are hydrophilic compounds with a small V<sub>d</sub>, thus distribution of rocuronium into adipose tissue is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10500937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10500937'])">Ref</a></span>). There are no studies evaluating the most appropriate weight metric in patients with obesity receiving sustained continuous infusions. Data with NMBAs in patients with obesity predominantly originate from studies evaluating either single bolus or incremental doses in patients undergoing surgical procedures.</p>
<p style="text-indent:-2em;margin-left:6em;">Although the manufacturer label suggests actual body weight for weight-based dosing, studies in patients with obesity where rocuronium was dosed according to actual body weight have demonstrated prolonged recovery times compared to weight-based dosing using other weight measures (eg, ideal body weight [IBW]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23463483','lexi-content-ref-28627976','lexi-content-ref-15385355','lexi-content-ref-26739976']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23463483','lexi-content-ref-28627976','lexi-content-ref-15385355','lexi-content-ref-26739976'])">Ref</a></span>). One study randomized patients with obesity (BMI ~44 kg/m<sup>2</sup>) to receive 0.6 mg/kg based on IBW or adjusted body weight (AdjBW) calculated using a correction factor of 0.2 or 0.4. This study showed no difference in onset of effect or intubation conditions among the 3 groups. The time to recovery was ~150% longer in the AdjBW (using 0.4 correction factor) group compared to the IBW group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19690247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19690247'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F219074"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F219085"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12774" href="/d/html/12774.html" rel="external">see "Rocuronium: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose to effect; doses will vary due to interpatient variability. Dosing also dependent on anesthetic technique and age of patient. In general, the onset of effect is shortened and duration is prolonged as the dose increases. The time to maximum nerve block is shortest in infants 1 to 3 months; the duration of relaxation is shortest in children 2 to 11 years and longest in infants. The manufacturer recommends dosing based on actual body weight in all obese patients; however, some have recommended dosing based on ideal body weight (IBW) in obese patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17683408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17683408'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e257107d-cfc8-4139-8489-2af70c1690f9">Neuromuscular blockade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuromuscular blockade:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ICU paralysis (eg, facilitate mechanical ventilation):</i> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35119438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35119438'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Intermittent IV dosing: IV: 0.6 mg/kg; repeat as needed.</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous IV infusion: 5 to 17 <b>mcg</b>/kg/minute (0.3 to 1 mg/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjunct to surgical anesthesia:</i>
<b>Note:</b> Inhaled anesthetic agents prolong the duration of action of rocuronium; use lower end of the dosing range; dosing interval guided by monitoring with a peripheral nerve stimulator.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">IV: Infants, Children, and Adolescents: IV: 0.45 to 0.6 mg/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">IM: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Anderson.1','lexi-content-ref-10485771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Anderson.1','lexi-content-ref-10485771'])">Ref</a></span>): <b>Note:</b> Due to the prolonged time to onset in some patients, IM dosing may not be ideal for tracheal intubation for the general population and should be reserved to clinical scenarios when alternative agents are not appropriate or IV access is not available.</p>
<p style="text-indent:-2em;margin-left:10em;">Infants ≥3 months: IM: 1 mg/kg administered as a single dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Children 1 to &lt;6 years: IM: 1.8 mg/kg administered as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance for continued surgical relaxation:</p>
<p style="text-indent:-2em;margin-left:8em;">Intermittent IV dosing: Infants, Children, and Adolescents: IV: 0.075 to 0.15 mg/kg; repeat as needed.</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous IV infusion: Infants, Children, and Adolescents: IV infusion: 7 to 12 <b>mcg</b>/kg/minute (0.42 to 0.72 mg/kg/<b>hour</b>); higher doses have been reported with prolonged infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8697549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8697549'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3b65e73-c545-4638-adf8-ee69e12a052b">Rapid sequence intubation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rapid sequence intubation:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Usual: 1 mg/kg; range: 0.6 to 1.2 mg/kg. <b>Note:</b> In children and adolescents, some studies found lower doses of 0.6 mg/kg resulted in prolonged time to onset, shortened duration of neuromuscular blockade and less favorable intubating conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-15123910','lexi-content-ref-11882225','lexi-content-ref-8949805','lexi-content-ref-9842809','lexi-content-ref-8694312','lexi-content-ref-9483596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-15123910','lexi-content-ref-11882225','lexi-content-ref-8949805','lexi-content-ref-9842809','lexi-content-ref-8694312','lexi-content-ref-9483596'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159919"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: No dosage adjustment necessary; duration of neuromuscular blockade may vary in patients with kidney impairment.</p></div>
<div class="block dohp drugH1Div" id="F51159920"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; use with caution in patients with clinically significant liver impairment. Due to increased volume of distribution in patients with liver disease, neuromuscular blockade may be prolonged; dosage reductions may be necessary. Adults with ascites requiring rapid sequence intubation may need higher initial doses to achieve adequate neuromuscular blockade.</p></div>
<div class="block adr drugH1Div" id="F219043"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Increased peripheral vascular resistance (abdominal aortic surgery: 24%, frequency not defined during other procedures), tachycardia (≤5%; incidence greater in children), hypertension, transient hypotension</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, asthma, cardiac arrhythmia, ECG abnormality, edema at insertion site, hiccups, nausea, pruritus, skin rash, vomiting</p></div>
<div class="block coi drugH1Div" id="F219057"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylaxis) to rocuronium, other neuromuscular-blocking agents, or any component of the formulation </p></div>
<div class="block war drugH1Div" id="F219041"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Have been reported; immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use is contraindicated in patients with previous anaphylactic reactions to other neuromuscular blockers.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prolonged paralysis: Some patients may experience prolonged recovery of neuromuscular function after administration (especially after prolonged use). Patients should be adequately recovered prior to extubation. Other factors associated with prolonged recovery should be considered (eg, corticosteroid use, patient condition).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Burn injury: Resistance may occur in burn patients (≥20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure); onset of action may be delayed and duration of action may be prolonged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions that may <i>antagonize</i> neuromuscular blockade (decreased paralysis): Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, and muscle trauma may result in antagonism of neuromuscular blockade (ACCM/SCCM/ASHP [Murray 2002]; Greenberg 2013; Miller 2010; Naguib 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions that may <i>potentiate</i> neuromuscular blockade (increased paralysis): Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), cachexia, neuromuscular diseases, metabolic acidosis, respiratory acidosis, Eaton-Lambert syndrome, and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg 2013; Miller 2010; Naguib 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; clinical duration may be prolonged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary hypertension: Use with caution in patients with pulmonary hypertension; use may increase pulmonary vascular resistance worsening symptoms of right heart failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with respiratory disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Valvular heart disease: Use with caution in patients with valvular heart disease; use may increase pulmonary vascular resistance.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use with caution in older adults, effects and duration are more variable.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immobilized patients: Resistance may occur in patients who are immobilized.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Not recommended by the manufacturer for rapid sequence intubation in pediatric patients; however, it has been used successfully in clinical trials for this indication (Cheng 2002; Fuchs-Buder 1996; Mazurek 1998; Naguib 1997).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Maintenance of an adequate airway and respiratory support is critical. Tolerance to rocuronium may develop. All patients should receive eye care including liberal use of lubricating drops, gel, or ointment and eyelids should remain closed during continuous neuromuscular blockade to protect against damage to the cornea (ulceration and drying).</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced personnel: Should be administered by adequately trained individuals familiar with its use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: If extravasation occurs, local irritation may ensue; discontinue administration immediately and restart in another vein.</p>
<p style="text-indent:-2em;margin-left:4em;">• Risk of medication errors: Accidental administration may be fatal. Confirm proper selection of intended product, store vial so the cap and ferrule are intact and the possibility of selecting the wrong product is minimized, and ensure that the intended dose is clearly labeled and communicated, when applicable.</p></div>
<div class="block foc drugH1Div" id="F219051"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (5 mL); 100 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as bromide [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (5 mL); 100 mg/10 mL (10 mL)</p></div>
<div class="block geq drugH1Div" id="F219037"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323798"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Rocuronium Bromide Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $0.37 - $3.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/10 mL (per mL): $0.60 - $3.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868187"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (5 mL)</p></div>
<div class="block adm drugH1Div" id="F219054"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> May be administered as a bolus injection (undiluted) or via a continuous infusion.</p></div>
<div class="block admp drugH1Div" id="F52613828"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer undiluted by rapid IM injection into the deltoid muscle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10485771','lexi-content-ref-8712436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10485771','lexi-content-ref-8712436'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Administer undiluted by rapid IV injection.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer undiluted or further diluted in a compatible diluent using an infusion pump (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ASHP.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ASHP.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F219052"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endotracheal intubation or mechanical ventilation during surgery, neuromuscular blockade:</b> As an adjunct to general anesthesia to facilitate rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation in adequately sedated ICU patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Neuromuscular blockade does not provide pain control, sedation, or amnestic effects. Appropriate analgesic and sedative mediations should be used before and during administration of neuromuscular blockade to achieve deep sedation.</p></div>
<div class="block off-label drugH1Div" id="F27628499"><span class="drugH1">Use: Off-Label: Adult</span><p>Mechanically ventilated patients in the ICU, neuromuscular blockade</p></div>
<div class="block mst drugH1Div" id="F219106"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Rocuronium may be confused with Romazicon</p>
<p style="text-indent:-2em;margin-left:4em;">Zemuron may be confused with Remeron, Zemplar.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">According to the 2020 to 2021 <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>, neuromuscular blockers should be segregated, sequestered, and differentiated from all other medication wherever they are stored. This includes:</p>
<p style="text-indent:-2em;margin-left:6em;">- Only storing in places within the hospital that they are routinely used.</p>
<p style="text-indent:-2em;margin-left:6em;">- Placing in sealed boxes or in rapid sequence intubation kits (preferred).</p>
<p style="text-indent:-2em;margin-left:6em;">- Limiting availability in automated dispensing cabinets to perioperative, labor and delivery, critical care, and emergency departments only.</p>
<p style="text-indent:-2em;margin-left:6em;">- Placing in separate lidded containers within the pharmacy refrigerator or other isolated pharmacy storage area.</p>
<p style="text-indent:-2em;margin-left:6em;">- Affixing an auxiliary label to clearly communicate respiratory paralysis will occur and ventilation required on all storage bins and/or automated dispensing pockets/drawers (exception anesthesia-prepared syringes) stating one of the following:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Warning: Causes Respiratory Arrest – Patient Must Be Ventilated.</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Warning: Paralyzing Agent – Causes Respiratory Arrest.</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Warning: Causes Respiratory Paralysis – Patient Must Be Ventilated.</b></p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300012"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F219045"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the therapeutic effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Management: If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and colistimethate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.  Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): May enhance the therapeutic effect of Rocuronium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Management: When initiating a non-depolarizing neuromuscular blocking agent (NMBA) in a patient receiving an inhalational anesthetic, initial NMBA doses should be reduced 15% to 25% and doses of continuous infusions should be reduced 30% to 60%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Management: If possible, avoid concomitant use of neuromuscular-blocking agents and polymyxin B. If concomitant use cannot be avoided, monitor for deeper, prolonged neuromuscular-blocking effects (eg, respiratory paralysis) in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimebutine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F219060"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Rocuronium crosses the placenta; umbilical venous plasma levels are ~18% of the maternal concentration following a maternal dose of 0.6 mg/kg (Abouleish 1994). The manufacturer does not recommend use for rapid sequence induction during cesarean section.</p></div>
<div class="block brc drugH1Div" id="F15683458"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Information related to rocuronium use and breast-feeding has not been located. If present in breast milk, oral absorption by a nursing infant would be expected to be minimal (Lee 1993).</p></div>
<div class="block mop drugH1Div" id="F219049"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Vital signs (heart rate, blood pressure, respiratory rate); degree of muscle paralysis (eg, presence of spontaneous movement, ventilator asynchrony, shivering, and consider use of a peripheral nerve stimulator with train of four monitoring along with clinical assessments)</p>
<p style="text-indent:-2em;margin-left:2em;">In the ICU setting, prolonged paralysis and generalized myopathy, following discontinuation of agent, may be minimized by appropriately monitoring degree of blockade.</p></div>
<div class="block pha drugH1Div" id="F219040"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks acetylcholine from binding to receptors on motor endplate inhibiting depolarization</p></div>
<div class="block phk drugH1Div" id="F219056"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children: 30 seconds to 1 minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Good intubation conditions within 1 to 3 minutes (dose dependent); maximum neuromuscular blockade within 4 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: 3 to 12 months: 40 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 1 to 12 years: 26 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~20 to 70 minutes (dose dependent, increases with higher doses and inhalational anesthetic agents); hypothermia may prolong the duration of action.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 0.21 to 0.3 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.25 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic dysfunction: 0.53 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Kidney dysfunction: 0.34 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~30%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimally hepatic; 17-desacetylrocuronium (5% to 10% activity of parent drug).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Alpha elimination: 1 to 2 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Beta elimination:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants 3 to 12 months: 1.3 ± 0.5 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 1 to &lt;3 years: 1.1 ± 0.7 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 3 to &lt;8 years: 0.8 ± 0.3 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 1.4 to 2.4 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic impairment: 4.3 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Kidney impairment: 2.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (50% to 75%); urine (up to 33% excreted in the urine) (Price 2012; Robertson 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Pediatric patients:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants 3 to &lt;12 months: 0.35 L/kg/hour.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 1 to &lt;3 years: 0.32 L/kg/hour.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 3 to &lt;8 years: 0.44 L/kg/hour.</p></div>
<div class="block phksp drugH1Div" id="F51159826"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is reduced by 39% in kidney failure, and recovery time (as measured by the time it takes for the train of four ratio to return to 0.7) is prolonged from 54 minutes in control patients to 88 minutes in patients with severe kidney impairment. Patients with kidney failure have higher interindividual variation in (and hence less predictable) durations of response compared to patients with normal kidney function (Robertson 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Patients with clinically significant hepatic impairment had moderately prolonged clinical duration; patients with cirrhosis had increased V<sub>d</sub>, prolonged plasma half-life, and &gt;2.5 times the recovery time compared to patients with normal hepatic function.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adults: Onset time and duration of action are slightly longer in older adults.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F219061"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Rocuron</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fada rocuronio | Rocunovag | Rocuronio kabi</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuroniumbromid B. Braun | Rocuroniumbromid hameln | Rocuroniumbromid hikma | Rocuroniumbromid Kabi | Rocuroniumbromid Sandoz</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Baxter rocuronium | DBL Rocuronium Bromide | Rocon | Rocuronium kabi | Rocuronium mylan | Rocuronium Sandoz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Rocuron</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rocuronium B. Braun | Rocuronium Sandoz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Rocuronium bromide fresenius Kabi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Brometo de rocuronio | Brometo de rocuronio hikma | Misck | Rocuron | Unirez</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronium fresenius | Rocuronium labatec | Rocuronium mepha | Rocuronium Sandoz</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bromuro de rocuronio | Bromuro rocuronio | Lufcuren | Rocuronio | Rocuronio bromuro</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronium B. Braun | Rocuronium bromide Hameln | Rocuronium fresenius kabi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronium inresa | Rocuroniumbromid B.Braun | Rocuroniumbromid hameln | Rocuroniumbromid Hexal | Rocuroniumbromid hikma | Rocuroniumbromid Hospira | Rocuroniumbromid Kabi | Rocuroniumbromid Pfizer | Rocuroniumbromid-ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuron</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bromuro de rocuronio | Esmeron | Flacidine | Rocuronio | Rocuronio bromuro</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Myocron | Rocuronium | Rocuronium bromide fresenius Kabi | Rocuronium bromide grindeks</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocubromide | Rocuroniumbromid hameln | Rocuthesia</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronio Braun | Rocuronio hospira | Rocuronio kabi</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Rocutroy</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronium B Brau | Rocuronium fresenius kabi | Rocuronium hameln | Rocuronium hospira</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rocuronium B Brau | Rocuronium Hikma | Rocuronium hospira | Rocuronium kabi | Rocuronium kalceks | Rocuronium mylan | Rocuronium noridem</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronium | Rocuronium Bromid Kabi</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Kabiroc | Noveron | Rocum | Rocuronium</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Kabiroc | Rocsur | Rocunium | Rocutroy</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronio b.braun | Rocuronio bromuro SALF | Rocuronio hikma | Rocuronio hospira | Rocuronio kabi | Rocuronio san | Rocuronio Sandoz</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rimexa | Rucoron</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Rocuronium</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Curoni | Dongkook rocuronium bromide | Esmeron | Kabi rocuronium | Rocaron | Rocnium | Rocumeron | Rocunium | Rocurin | Rocuron | Romeron</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocurocel | Rocuronium bromide kalceks | Rocuronium hameln | Rocuronium Hikma | Roqurum</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronium bromide kalceks</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Curionialis | Desproxyl | Esmeron | Lufcuren | Mirontrex | Neolblock | Pablax | Robulvar | Rocuronio | Somtus</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocsur | Rocuronium hameln | Rocuronium kabi</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuroniumbromide erc | Rocuroniumbromide eureco pharma | Rocuroniumbromide Fresenius Kabi | Rocuroniumbromide hospira | Rocuroniumbromide ratiopharm | Rocuroniumbromide Sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow rocuronium | Esmeron</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bromuro rocuronio | Esmeron | Flacidine | Rocsur | Rocubron | Rocuronio | Rocuronio bromuro | Romeron</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Kabiroc | Rocuron | Rocuronium</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronium Braun | Rocuronium bromide Hameln | Rocuronium kabi | Roqurum</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Rocuronium | Zemuron</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Brometo de rocuronio hikma | Esmeron</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Kruaron | Rocuronium | Rocuronium binergy | Rocuronium kabi</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronium | Rucoron</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronium B. Braun | Rocuronium fresenius kabi | Rocuronium hameln | Rocuronium hospira</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronium B.Braun | Rocuronium bromide Hameln | Rocuronium bromide kalceks | Rocuronium fresenius kabi | Rocuxant</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Esmeron</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Antarin | Curon | Esmeron | Jecron | Muscuron | Myocron</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocurin | Rocuronium | Rocuronium hameln</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Esmeron | Rocuronio kabi</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Rocutroy</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Rocuron | Zemuron</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Rocur | Rocuronio bromuro</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco rocuronium | Antarin | Erunom | Esmeron | Rocuronium fresenius | Trakeze</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-7946860">
<a name="7946860"></a>Abouleish E, Abboud T, Lechevalier T, et al. Rocuronium (Org 9426) for Caesarean Section. <i>Br J Anaesth</i>. 1994;73(3):336-341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/7946860/pubmed" id="7946860" target="_blank">7946860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34281428">
<a name="34281428"></a>Aldhaeefi M, Dube KM, Kovacevic MP, Szumita PM, Lupi KE, DeGrado JR. Evaluation of rocuronium continuous infusion in critically ill patients during the COVID-19 pandemic and drug shortages. <i>J Pharm Pract</i>. 2021:8971900211033138. doi:10.1177/08971900211033138<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/34281428/pubmed" id="34281428" target="_blank">34281428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33104824">
<a name="33104824"></a>Alhazzani W, Belley-Cote E, Møller MH, et al. Neuromuscular blockade in patients with ARDS: a rapid practice guideline. <i>Intensive Care Med</i>. 2020;46(11):1977-1986. doi:10.1007/s00134-020-06227-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/33104824/pubmed" id="33104824" target="_blank">33104824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed November 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Anderson.1">
<a name="Anderson.1"></a>Anderson BJ, Lerman J, and Coté CJ. Pharmacokinetics and Pharmacology of Drugs Used in Children. In: Coté CJ, Lerman J, Anderson B, eds. A Practice of Anesthesia for Infants and Children. 6th ed. Saunders Elsevier; 2017: 150.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9059214">
<a name="9059214"></a>Barclay K, Eggers K, and Asai T .Low-Dose Rocuronium Improves Conditions for Tracheal Intubation After Induction of Anaesthesia With Propofol and Alfentanil. <i>Br J Anaesth</i>. 1997;78(1):92-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9059214/pubmed" id="9059214" target="_blank">9059214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8103649">
<a name="8103649"></a>Bartkowski RR, Witkowski TA, Azad S, et al. Rocuronium Onset of Action: A Comparison With Atracurium and Vecuronium. <i>Anesth Analg</i>. 1993;77(3):574-578.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8103649/pubmed" id="8103649" target="_blank">8103649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15123910">
<a name="15123910"></a>Bledsoe GH, Schexnayder SM. Pediatric rapid sequence intubation: a review. <i>Pediatr Emerg Care</i>. 2004;20(5):339-344. doi:10.1097/01.pec.0000125667.58561.62<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/15123910/pubmed" id="15123910" target="_blank">15123910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Caro.2023">
<a name="Caro.2023"></a>Caro D. Neuromuscular blocking agents (NMBAs) for rapid sequence intubation in adults for emergency medicine and critical care. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed June 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11882225">
<a name="11882225"></a>Cheng CA, Aun CST, Gin T. Comparison of Rocuronium and Suxamethonium for Rapid Tracheal Intubation in Children. <i>Paediatr Anaesth</i>. 2002;12(2):140-145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/11882225/pubmed" id="11882225" target="_blank">11882225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11020136">
<a name="11020136"></a>Cheymol G. Effects of Obesity on Pharmacokinetics: Implications for Drug Therapy. <i>Clin Pharmacokinet</i>. 2000;39(3):215-231.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/11020136/pubmed" id="11020136" target="_blank">11020136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8123396">
<a name="8123396"></a>Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, Fitzpatrick KT. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure.<i> Br J Anaesth</i>. 1993;71(2):222-226. doi:10.1093/bja/71.2.222<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8123396/pubmed" id="8123396" target="_blank">8123396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19222432">
<a name="19222432"></a>Craig RG, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. <i>Anaesthesia</i>. 2009;64(suppl 1):55-65. doi:10.1111/j.1365-2044.2008.05871.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/19222432/pubmed" id="19222432" target="_blank">19222432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37196592">
<a name="37196592"></a>Engstrom K, Brown CS, Mattson AE, Lyons N, Rech MA. Pharmacotherapy optimization for rapid sequence intubation in the emergency department. <i>Am J Emerg Med</i>. 2023;70:19-29. doi:10.1016/j.ajem.2023.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/37196592/pubmed" id="37196592" target="_blank">37196592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14625670">
<a name="14625670"></a>Erstad BL. Dosing of Medications in Morbidly Obese Patients in the Intensive Care Unit Setting. <i>Intensive Care Med</i>. 2004;30(1):18-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/14625670/pubmed" id="14625670" target="_blank">14625670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care</i>
<i>Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8949805">
<a name="8949805"></a>Fuchs-Buder T, Tassonyi E. Intubating Conditions and Time Course of Rocuronium-Induced Neuromuscular Block in Children. <i>Br J Anaesth</i>. 1996;77(3):335-338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8949805/pubmed" id="8949805" target="_blank">8949805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463483">
<a name="23463483"></a>Fujimoto M, Tanahira C, Nishi M, Yamamoto T. In non-obese patients, duration of action of rocuronium is directly correlated with body mass index. <i>Can J Anaesth.</i> 2013;60(6):552-556. doi:10.1007/s12630-013-9914-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/23463483/pubmed" id="23463483" target="_blank">23463483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21562423">
<a name="21562423"></a>Gaszynski TM, Szewczyk T. Rocuronium for rapid sequence induction in morbidly obese patients: a prospective study for evaluation of intubation conditions after administration 1.2 mg kg<sup>-1 </sup>ideal body weight of rocuronium. <i>Eur J Anaesthesiol</i>. 2011;28(8):609-611. doi:10.1097/EJA.0b013e32834753d0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/21562423/pubmed" id="21562423" target="_blank">21562423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23591211">
<a name="23591211"></a>Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? <i>Crit Care Med</i>. 2013;41(5):1332-1344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/23591211/pubmed" id="23591211" target="_blank">23591211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31846014">
<a name="31846014"></a>Guihard B, Chollet-Xémard C, Lakhnati P, et al. Effect of rocuronium vs succinylcholine on endotracheal intubation success rate among patients undergoing out-of-hospital rapid sequence intubation: a randomized clinical trial. <i>JAMA</i>. 2019;322(23):2303-2312. doi:10.1001/jama.2019.18254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/31846014/pubmed" id="31846014" target="_blank">31846014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19029093">
<a name="19029093"></a>Han TH and Martyn JAJ. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus.<i>Br J Anaesth</i>. 2009, 102(1):55-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/19029093/pubmed" id="19029093" target="_blank">19029093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hansen.1">
<a name="Hansen.1"></a>Hansen AR, Stark AR, Eichenwald EC, Martin CR. Appendix B: Intubation Sedation Guidelines. In: Hansen AR, Stark AR, Eichenwald EC, Martin CR, eds. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9728861">
<a name="9728861"></a>Harvey SC, Roland P, Bailey MK, et al, "A Randomized, Double-Blind Comparison of Rocuronium, d-Tubocurarine, and 'Mini-Dose' Succinylcholine for Preventing Succinylcholine-Induced Muscle Fasciculations," <i>Anesth Analg</i>, 1998, 87(3):719-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9728861/pubmed" id="9728861" target="_blank">9728861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34702332">
<a name="34702332"></a>Honing M, Reijnders-Boerboom G, Dell-Kuster S, et al. The impact of deep versus standard neuromuscular block on intraoperative safety during laparoscopic surgery: an international multicenter randomized controlled double-blind strategy trial - EURO-RELAX TRIAL. <i>Trials</i>. 2021;22(1):744. doi:10.1186/s13063-021-05638-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/34702332/pubmed" id="34702332" target="_blank">34702332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice (ISMP). <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>. https://ismp.org/guidelines/best-practices-hospitals. Published February 21, 2020. Accessed August 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28627976">
<a name="28627976"></a>Jing Z, Muheremu A, Liu P, Hu X, Binjiang Z. Administration of rocuronium based on real body weight versus fat-free mass in patients with lymphedema. <i>J Int Med Res.</i> 2017;45(6):2072-2077. doi:10.1177/0300060517711085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/28627976/pubmed" id="28627976" target="_blank">28627976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10485771">
<a name="10485771"></a>Kaplan RF, Uejima T, Lobel G, et al. Intramuscular rocuronium in infants and children: A multicenter study to evaluate tracheal intubating conditions, onset, and duration of action. <i>Anesthesiology</i>. 1999;91(3):633-638.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/10485771/pubmed" id="10485771" target="_blank">10485771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8557012">
<a name="8557012"></a>Khuenl-Brady KS, Sparr H, Puhringer F, et al, “Rocuronium Bromide in the ICU: Dose Finding and Pharmacokinetics,” <i>Eur J Anaesthesiol Suppl</i>, 1995, 11:79-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8557012/pubmed" id="8557012" target="_blank">8557012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30572545">
<a name="30572545"></a>Ko MJ, Oh B, Jung JW, et al. Comparing the effect between continuous infusion and intermittent bolus of rocuronium for intraoperative neurophysiologic monitoring of neurointervention under general anesthesia.<i> Medicine (Baltimore)</i>. 2018;97(51):e13816. doi:10.1097/MD.0000000000013816<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/30572545/pubmed" id="30572545" target="_blank">30572545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20176672">
<a name="20176672"></a>Kumar P, Denson SE, Mancuso TJ; Committee on Fetus and Newborn, Section on Anesthesiology and Pain Medicine. Premedication for nonemergency endotracheal intubation in the neonate. <i>Pediatrics</i>. 2010;125(3):608-615.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/20176672/pubmed" id="20176672" target="_blank">20176672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8346780">
<a name="8346780"></a>Lee JJ and Rubin AP, "Breast Feeding and Anaesthesia," <i>Anaesthesia</i>, 1993, 48(7):616-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8346780/pubmed" id="8346780" target="_blank">8346780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33837951">
<a name="33837951"></a>Levin NM, Fix ML, April MD, Arana AA, Brown CA 3rd; NEAR Investigators. The association of rocuronium dosing and first-attempt intubation success in adult emergency department patients. <i>CJEM</i>. 2021;23(4):518-527. doi:10.1007/s43678-021-00119-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/33837951/pubmed" id="33837951" target="_blank">33837951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15385355">
<a name="15385355"></a>Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. <i>Anesth Analg.</i> 2004;99(4):1086-1089. doi:10.1213/01.ANE.0000120081.99080.C2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/15385355/pubmed" id="15385355" target="_blank">15385355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7902034">
<a name="7902034"></a>Magorian T, Flannery KB, Miller RD. Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients.<i> Anesthesiology</i>. 1993;79(5):913-918. doi:10.1097/00000542-199311000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/7902034/pubmed" id="7902034" target="_blank">7902034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10446832">
<a name="10446832"></a>Martin LD, Bratton SL, and O'Rourke PP, “Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children,” <i>Crit Care Med</i>, 1999, 27(7):1358-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/10446832/pubmed" id="10446832" target="_blank">10446832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9669004">
<a name="9669004"></a>Martin R, Carrier J, Pirlet M, et al, "Rocuronium is the Best Non-Depolarizing Relaxant to Prevent Succinylcholine Fasciculations and Myalgia," <i>Can J Anaesth</i>, 1998, 45(6):521-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9669004/pubmed" id="9669004" target="_blank">9669004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9842809">
<a name="9842809"></a>Mazurek AJ, Rae B, Hann S, et al. Rocuronium versus succinylcholine: Are they equally effective during rapid-sequence induction of anesthesia?” <i>Anesth Analg</i>. 1998;87:1259-1262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9842809/pubmed" id="9842809" target="_blank">9842809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30567922">
<a name="30567922"></a>McPherson C. Premedication for endotracheal intubation in the neonate. <i>Neonatal Netw</i>. 2018;37(4):238-247. doi:10.1891/0730-0832.37.4.238<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/30567922/pubmed" id="30567922" target="_blank">30567922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19690247">
<a name="19690247"></a>Meyhoff CS, Lund J, Jenstrup MT, et al. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? <i>Anesth Analg</i>. 2009;109(3):787-792. doi:10.1213/ane.0b013e3181b0826a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/19690247/pubmed" id="19690247" target="_blank">19690247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.1">
<a name="Miller.1"></a>Miller RD, <i>Miller’s Anesthesia</i>, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11902255">
<a name="11902255"></a>Murray MJ, Cowen J, DeBlock H, et al; Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. <i>Crit Care Med</i>. 2002;30(1):142-156. doi:10.1097/00003246-200201000-00021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/11902255/pubmed" id="11902255" target="_blank">11902255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27755068">
<a name="27755068"></a>Murray MJ, DeBlock H, Erstad B, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. <i>Crit Care Med</i>. 2016;44(11):2079-2103. doi: 10.1097/CCM.0000000000002027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/27755068/pubmed" id="27755068" target="_blank">27755068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11753022">
<a name="11753022"></a>Naguib M, Flood P, McArdle JJ, et al. Advances in neurobiology of the neuromuscular junction. Implications for the anesthesiologist. <i>Anesthesiology</i>. 2002; 96(1): 202-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/11753022/pubmed" id="11753022" target="_blank">11753022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9389261">
<a name="9389261"></a>Naguib M, Samarkandi AH, Ammar A, et al. Comparison of suxamethonium and different combinations of rocuronium and mivacurium for rapid tracheal intubation in children. <i>Br J Anaesth.</i> 1997;79(4):450-455.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9389261/pubmed" id="9389261" target="_blank">9389261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28814478">
<a name="28814478"></a>Patanwala AE, Sakles JC. Effect of patient weight on first pass success and neuromuscular blocking agent dosing for rapid sequence intubation in the emergency department. <i>Emerg Med J</i>. 2017;34(11):739-743. doi:10.1136/emermed-2017-206762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/28814478/pubmed" id="28814478" target="_blank">28814478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28814478">
<a name="28814478"></a>Plaud B, Baillard C, Bourgain JL, et al. Guidelines on muscle relaxants and reversal in anaesthesia. <i>Anaesth Crit Care Pain Med</i>. 2020;39(1):125-142. doi:10.1016/j.accpm.2020.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/28814478/pubmed" id="28814478" target="_blank">28814478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17683408">
<a name="17683408"></a>Playfor S, Jenkins I, Boyles C, et al. Consensus guidelines for sustained neuromuscular blockade in critically ill children. <i>Paediatr Anaesth</i>. 2007;17(9):881-887.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/17683408/pubmed" id="17683408" target="_blank">17683408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23062076">
<a name="23062076"></a>Price D, Kenyon NJ, Stollenwerk N. A fresh look at paralytics in the critically ill: real promise and real concern. <i>Ann Intensive Care</i>. 2012;2(1):43. doi:10.1186/2110-5820-2-43<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/23062076/pubmed" id="23062076" target="_blank">23062076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11094587">
<a name="11094587"></a>Proost JH, Eriksson LI, Mirakhur RK, et al. Urinary, biliary and faecal excretion of rocuronium in humans. <i>Br J Anaesth</i>. 2000;85(5):717-723.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/11094587/pubmed" id="11094587" target="_blank">11094587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10500937">
<a name="10500937"></a>Pühringer FK, Keller C, Kleinsasser A, Giesinger S, Benzer A. Pharmacokinetics of rocuronium bromide in obese female patients. <i>Eur J Anaesthesiol</i>. 1999;16(8):507-510. doi:10.1046/j.1365-2346.1999.00523.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/10500937/pubmed" id="10500937" target="_blank">10500937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8556996">
<a name="8556996"></a>Puhringer FK, Khuenl-Brady KS, Mitterschiffthaler G. Rocuronium Bromide: Time-Course of Action in Underweight, Normal Weight, Overweight and Obese Patients. <i>Eur J Anaesthesiol Suppl</i>. 1995;11:107-110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8556996/pubmed" id="8556996" target="_blank">8556996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9366462">
<a name="9366462"></a>Reynolds LM, Lau M, Brown R, et al, “Bioavailability of Intramuscular Rocuronium in Infants and Children,” <i>Anesthesiology</i>, 1997, 87(5):1096-105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9366462/pubmed" id="9366462" target="_blank">9366462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8712436">
<a name="8712436"></a>Reynolds LM, Lau M, Brown R, Luks A, Fisher DM. Intramuscular rocuronium in infants and children. Dose-ranging and tracheal intubating conditions. <i>Anesthesiology</i>. 1996;85(2):231-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8712436/pubmed" id="8712436" target="_blank">8712436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15816565">
<a name="15816565"></a>Robertson EN, Driessen JJ, Booij LH. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. <i>Eur J Anaesthesiol.</i> 2005;22(1):4-10. doi:10.1017/s0265021505000025.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/15816565/pubmed" id="15816565" target="_blank">15816565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxter.1">
<a name="Baxter.1"></a>Rocuronium bromide [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Almaject.1">
<a name="Almaject.1"></a>Rocuronium bromide [prescribing information]. Morristown, NJ: Almaject, Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8835051">
<a name="8835051"></a>Rudis MI, Guslits BG, and Zarowitz BJ, “Technical and Interpretive Problems of Peripheral Nerve Stimulation in Monitoring Neuromuscular Blockade in the Intensive Care Unit,” <i>Ann Pharmacother</i>, 1996, 30(2):165-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8835051/pubmed" id="8835051" target="_blank">8835051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26739976">
<a name="26739976"></a>Sakızcı-Uyar B, Çelik S, Postacı A, et al. Comparison of the effect of rocuronium dosing based on corrected or lean body weight on rapid sequence induction and neuromuscular blockade duration in obese female patients. <i>Saudi Med J</i>. 2016;37(1):60-65. doi:10.15537/smj.2016.1.14099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/26739976/pubmed" id="26739976" target="_blank">26739976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8694312">
<a name="8694312"></a>Scheiber G, Ribeiro FC, Marichal A, Bredendiek M, Renzing K. Intubating conditions and onset of action after rocuronium, vecuronium, and atracurium in young children. <i>Anesth Analg</i>. 1996;83(2):320-324. doi:10.1097/00000539-199608000-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8694312/pubmed" id="8694312" target="_blank">8694312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Siegel.2018">
<a name="Siegel.2018"></a>Siegel MD. Acute respiratory distress syndrome: Supportive care and oxygenation in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed February 15, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35119438">
<a name="35119438"></a>Smith HAB, Besunder JB, Betters KA, et al. 2022 Society of Critical Care Medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. <i>Pediatr Crit Care Med</i>. 2022;23(2):e74-e110. doi:10.1097/PCC.0000000000002873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/35119438/pubmed" id="35119438" target="_blank">35119438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9135303">
<a name="9135303"></a>Sparr HJ, Wierda JM, Proost JH, et al, “Pharmacodynamics and Pharmacokinetics of Rocuronium in Intensive Care Patients,” <i>Br J Anaesth</i>, 1997, 78(3):267-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9135303/pubmed" id="9135303" target="_blank">9135303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9483596">
<a name="9483596"></a>Stoddart PA, Mather SJ. Onset of neuromuscular blockade and intubating conditions one minute after the administration of rocuronium in children. <i>Paediatr Anaesth</i>. 1998;8(1):37-40. doi:10.1046/j.1460-9592.1998.00719.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/9483596/pubmed" id="9483596" target="_blank">9483596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35223887">
<a name="35223887"></a>Tang L, Zhao X, Li S, et al. Impact of succinylcholine vs. rocuronium on apnea duration for rapid sequence induction: a prospective cohort study. <i>Front Med (Lausanne)</i>. 2022;9:717477. doi:10.3389/fmed.2022.717477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/35223887/pubmed" id="35223887" target="_blank">35223887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8697549">
<a name="8697549"></a>Tobias JD. Continuous infusion of rocuronium in a paediatric intensive care unit. <i>Can J Anaesth</i>. 1996;43(4):353-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/8697549/pubmed" id="8697549" target="_blank">8697549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31025258">
<a name="31025258"></a>Veelo DP, Gisbertz SS, Binnekade JM, et al. On-demand versus continuous rocuronium infusion for deep neuromuscular relaxation in patients undergoing thoraco-laparoscopic esophagectomy: a randomized-controlled clinical trial (DEPTH). <i>Can J Anaesth</i>. 2019;66(9):1062-1074. doi:10.1007/s12630-019-01373-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/31025258/pubmed" id="31025258" target="_blank">31025258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21828347">
<a name="21828347"></a>Warr J, Thiboutot Z, Rose L, et al, “Current Therapeutic Uses, Pharmacology, and Clinical Considerations of Neuromuscular Blocking Agents for Critically Ill Adults,” <i>Ann Pharmacother</i>, 2011, 45(9):1116-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/21828347/pubmed" id="21828347" target="_blank">21828347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Willets.1">
<a name="Willets.1"></a>Willets LS, “Rocuronium for Tracheal Intubation,” <i>Ped Pharmacotherapy</i>, 2000, 6(10):1-6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zemuron.1">
<a name="Zemuron.1"></a>Zemuron (rocuronium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34750839">
<a name="34750839"></a>Zhang X, Hu H, Yan R, Li T, Wang W, Yang W. Effects of rocuronium dosage on intraoperative neurophysiological monitoring in patients undergoing spinal surgery. <i>J Clin Pharm Ther</i>. 2022;47(3):313-320. doi:10.1111/jcpt.13557<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rocuronium-drug-information/abstract-text/34750839/pubmed" id="34750839" target="_blank">34750839</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9872 Version 379.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
